Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes
This does not mean retatrutide is better or more suitable than existing licensed treatments
Both peptides are part of the growth hormone-releasing hormone (GHRH) family and are acknowledged for their capacity to affect the patterns linked with GH release
Eng C, Kramer CK, Zinman B, Retnakaran R
In Phase 2 research, this pharmacological profile translated into the largest average weight reductions ever reported for a once-weekly peptide, catalyzing widespread interest among endocrinologists, obesity researchers, and metabolic-disease scientists
